5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma

Table 1 clinicopathologic parameters of 110 hepatocellular carcinoma patients, n (%)

Characteristics	Patients	5’-tiRNA-Lys-CTT		P value
		High	Low
Number	110	55 (50)	55 (50)
Gender				0.2343
Male	70 (63.6)	38 (34.5)	32 (29.1)
Female	40 (36.4)	17 (15.5)	23 (20.9)
Age (years)				0.6884
< 60	38 (34.5)	18 (16.4)	20 (18.2)
≥ 60	72 (65.5)	37 (33.6)	35 (31.8)
Tumor size (cm)				0.0174a
< 5	40 (36.4)	26 (23.6)	14 (12.7)
≥ 5	70 (63.6)	29 (26.4)	41 (37.3)
BCLC stage				0.0064b
0/A	44 (40.0)	29 (26.4)	15 (13.6)
B/C/D	66 (60.0)	26 (23.6)	40 (36.4)
Tumor differentiation				0.2290
Well/moderate	72 (65.5)	39 (35.5)	33 (30.0)
Poor	38 (34.5)	16 (14.5)	22 (20.0)
Metastasis				0.0348
Negative	49 (44.5)	30 (27.3)	19 (17.3)
Positive	61 (55.5)	25 (22.7)	36 (32.7)
Cirrhosis of the liver				0.0161a
Absence	38 (34.5)	13 (11.8)	25 (22.7)
Presence	72 (65.5)	42 (38.2)	30 (27.3)

^aP < 0.05.

^bP < 0.01.

BCLC: Barcelona Clinic Liver Cancer.